[Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].

ABSTRACT:

Objective

To evaluate the value of pharmacogenetic testing for improving the efficacy and safety of treatment with cyclosporine, tacrolimus, and cyclophosphamide (CTX) for PLA2R-related membranous nephropathy and for determing individualized and precise treatment plans for the patients.

Methods

A total of 63 patients with PLA2R-related membranous nephropathy hospitalized in the Department of Nephrology at our hospital from January, 2019 to October, 2021 were enrolled in this study. Thirty-three of the patients underwent pharmacogenetic testing before taking the immunosuppressive drugs selected based on the results of genetic screening for sensitive targets, and the other 30 patients were empirically given immunosuppressive drugs according to the guidelines (control group). T

SUBMITTER: Tan T 

PROVIDER: S-EPMC10339295 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature